参考文献 References
[1] International Diabetes Federa tion. IDF Diabetes Atlas, 10th edition [EB/OL]. Brussels, Belgium: 2021; Available at: https :// www.diabetesatlas.org
[2] Xu, Y., Lu, J., Li, M., Wang, T., Wang, K., Cao, Q., Ding, Y., Xiang, Y., Wang, S., Yang, Q., Zhao, X., Zhang, X., Xu, M., Wang, W., Bi, Y., & Ning, G. (2024). Diabetes in China part 1: epidemiology and risk factors [J]. The Lancet Public Health. 2024,9(12):e1089-e1097.
[3] Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, Shi B, Sun H, Ba J, Chen B, Du J, He L, Lai X, Li Y, Chi H, Liao E, Liu C, Liu L, Tang X, Tong N, Wang G, Zhang JA, Wang Y, Xue Y, Yan L, Yang J, Yang L, Yao Y, Ye Z, Zhang Q, Zhang L, Zhu J, Zhu M, Ning G, Mu Y, Zhao J, Teng W, Shan Z. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study [J]. BMJ. 2020 ,369:M997.
[4] Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research[J]. Medicina (Kaunas). 2019, 55(09): 546.
[5] 中华医学会糖尿病学分会.中国糖尿病防治指南(2024版)[J].中华糖尿病杂志,2025,17(01):16-139.
[6] 仝小林,贾伟平,王秀阁,等.糖尿病前期治未病干预指南[J].吉林中医药,2025,45(03):249-255.
[7] 杨茂林.芪玉降糖膏对2型糖尿病的治疗效果分析[J].海峡药学,2021,33(03):134-135.
[8] 朱泳江,富晓旭,谢春光.“饮一溲二”病名病机浅析[J].北京中医药大学学报,2024,47(03):320-324.
[9] 王宇,王鹤迪,陈强,等.中医经典名方治疗糖尿病的研究进展[J].中国实验方剂学杂志,2025,31(04):266-277.
[10] 汪道贵,刘火锋,周华.消渴方加减治疗2型糖尿病肾病患者(气虚血瘀型)的临床研究[J/OL].中华中医药学刊,1-9[2025-05-15].
http://kns.cnki.net/kcms/detail/21.1546.r.20250220.1715.004.html.
[11] 吴海芳,张辉,李淳.何庆勇主任医师运用白虎加人参汤经验[J].中国医药导报,2024,21(15):135-137.
[12] 侯亚莉,张雨,林梅.白虎加人参汤对2型糖尿病患者氧化应激水平与胰岛素敏感性的影响[J].中药药理与临床,2017,33(05):192-194.
[13] 袁晗,邓小敏.六味地黄丸从肾论治糖尿病研究进展[J].光明中医,2024,39(21):4418-4421.
[14] Wenjie Zheng, Gaofeng Wang, Zhe Zhang, Zhenguo Wang, Ke Ma,Research progress on classical traditional Chinese medicine formula Liuwei Dihuang pills in the treatment of type 2 diabetes[J]. Biomedicine & Pharmacotherapy,2020, 121:109564.
[15] Lu X, Xie Q, Pan X, Zhang R, Zhang X, Peng G, Zhang Y, Shen S, Tong N. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy[J]. Signal Transduct Target Ther,2024,9(1):262.
[16] International Diabetes Federation. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes – 2025.https://idf.org/t2d-cpr-2025.
[17] Warrilow, A., Somerset, S., Pumpa, K. et al.Metformin use in prediabetes: is earlier intervention better? [J]. Acta Diabetol,2020,57(11):1359-1366.
[18] André J Scheen a. SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes? [J]. Revue medicale Suisse. 2019, 14(615):1460-1465.
[19] Ji L, Dong X, Li Y, Li Y, Lim S, Liu M, Ning Z, Rasmussen S, Skjøth TV, Yuan G, Eliaschewitz FG. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab. 2021, 23(2): 404-414.
[20] 王晓红,王慧,石广珠,等.滋阴清热方联合胰岛素皮下泵治疗初发2型糖尿病患者的临床研究[J].医学食疗与健康,2019,(17):34-35.
[21] Galaviz KI, Weber MB, Suvada K BS, Gujral UP, Wei J, Merchant R, Dharanendra S, Haw JS, Narayan KMV, Ali MK. Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis[J]. Am J Prev Med. 2022,62(4):614-625.
[22] Beulens J, Rutters F, Rydén L, Schnell O, Mellbin L, Hart HE, Vos RC. Risk and management of pre-diabetes[J]. Eur J Prev Cardiol. 2019,26(2):47-54.